Encephalomyelitis : A New Paradigm for the Treatment of Multiple Sclerosis Endogenous Opioids Regulate Expression of Experimental Autoimmune

@inproceedings{Zagon2009EncephalomyelitisA,
  title={Encephalomyelitis : A New Paradigm for the Treatment of Multiple Sclerosis Endogenous Opioids Regulate Expression of Experimental Autoimmune},
  author={Ian S. Zagon and Kristen A. Rahn and Anthony P. Turel and P J Mclaughlin},
  year={2009}
}
Preclinical investigations utilizing murine experimental auto-immune encephalomyelitis (EAE), as well as clinical observations in patients with multiple sclerosis (MS), may suggest alteration of endogenous opioid systems in MS. In this study we used the opioid antagonist naltrexone (NTX) to invoke a continuous (High Dose NTX, HDN) or intermittent (Low Dose NTX, LDN) opioid receptor blockade in order to elucidate the role of native opioid peptides in EAE. A mouse model of myelin oligodendrocyte… CONTINUE READING